• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Toolbar - View Selection
 
Items 1 of 1
ALX-270-379 Revised 04-Mar-05
Oxamflatin
Add to Clipboard
SYNONYMS (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic acid
PRODUCT LINE Cancer
PRODUCT CATEGORY Antitumor Agents (Apoptosis Inducers)
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-379-M001   1 mg 70.00 USD Add To Cart
ALX-270-379-M005   5 mg 275.00 USD Add To Cart
Inquire
Product Specification
FORMULA: C17H14N2O4S
MW: 342.4
PURITY: ≥95% (HPLC)
APPEARANCE: Solid.
SOLUBILITY: Soluble in DMSO, methanol or acetonitrile.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: +4°C
HANDLING: After reconstitution, prepare aliquots and store at -20°C. Packaged under inert gas. Protect from light.

Product Description
Potent inhibitor of mammalian HDAC (IC50=15.7nM). Acts as a ligand for the enzyme active site metal ion. Upregulates plasminogen activator inhibitor type 2 (PAI-2) expression with concomitant inhibition of urokinase (u-PA) gene and protein expression in HT-1080 and U-937 cells. Elevates the expression of extracellular matrix proteins fibronectin and gelsolin. Induces apoptosis in P-glyoprotein (Pgp) positive and Pgp negative multidrug resistant cells.
Product Specific Literature References
Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD: H. Sonoda, et al.; Oncogene 13, 143 (1996) Abstract
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase: Y.B. Kim, et al.; Oncogene 18, 2461 (1999) Abstract
The novel anti-tumour agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activity: A.E. Dear & R.L. Medcalf; Biochim. Biophys. Acta 1492, 15 (2000) Abstract
Novel mechanisms of apoptosis induced by histone deacetylase inhibitors: M.J. Peart, et al.; Cancer Res. 63, 4460 (2003) Abstract
 
 

Your items will be kept only for the duration of your visit.